pharmaphorum November 25, 2021
Ieso has raised $53 million in second-round financing that will be used to bring its digital therapeutics (DTx) through to market in its home market of the UK, as well as the US.
The company’s artificial intelligence-powered software uses cognitive behavioural therapy techniques to help patients suffering from a range of mental health issues, including depression and anxiety.
The cash injection is earmarked for getting the DTx products through regulatory approvals in the UK and US, and building commercial teams.
It was led by Morningside, alongside new investors including Sony Innovation Fund and further participation from existing shareholders, IP Group, Molten Ventures and Ananda Impact Ventures. Morningside’s Stephen Bruso is joining Ieso’s board.
Ieso’s offers therapist-led online CBT programmes for...
Today's Sponsors
Today's Sponsor